Clinical Outcome of Delayed or Standard Prograf Together with Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or circulatory) Death (DCD) Kidney Transplant Recipients

Trial Identifier: 506-MA-3186
Sponsor: Astellas Pharma China, Inc.
Start Date: October 2018
Primary Completion Date: July 2022
Study Completion Date: July 2022
Condition: Kidney Transplants

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Beijing, China
China Changsha, China
China Guangzhou, China
China Hangzhou, China
China Nanjing, China
China Shanghai, China
China Tianjin, China
China Wenzhou, China
China Xi'an, China